title: Clinical manifestations, response to treatment, and clinical outcome for Weimaraners with hypertrophic osteodystrophy: 53 cases (2009-2011).
abstract: OBJECTIVE
  To evaluate clinical manifestations, response to treatment, and outcome for Weimaraners with hypertrophic osteodystrophy (HOD).
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  53 dogs.
  
  
  METHODS
  Medical records were reviewed for signalment, vaccination history, clinical signs, laboratory test results, response to treatment, and relapses. Radiographs were reviewed.
  
  
  RESULTS
  Clinical signs included pyrexia, lethargy, and ostealgia; signs involving the gastrointestinal, ocular, or cutaneous systems were detected. Of the 53 dogs, 28 (52.8%) had HOD-affected littermates. Dogs with HOD-affected littermates were more likely to relapse, compared with the likelihood of relapse for dogs with no HOD-affected littermates. All 53 dogs had been vaccinated 1 to 30 days before HOD onset; no difference was found between the number of dogs with a history of vaccination with a recombinant vaccine (n … 21) versus a nonrecombinant vaccine (32). Fifty (94.3%) dogs had radiographic lesions compatible with HOD at disease onset, and the other 3 (5.7%) had HOD lesions 48 to 72 hours after the onset of clinical signs. Twelve of 22 (54.5%) dogs treated with NSAIDs did not achieve remission by 7 days after initiation of treatment. All dogs treated initially with corticosteroids achieved remission within 8 to 48 hours. Of the 33 dogs that reached adulthood, 28 (84.8%) were healthy and 5 (15.2%) had episodes of pyrexia and malaise.
  
  
  CONCLUSIONS
  Treatment with corticosteroids was superior to treatment with NSAIDs in Weimaraners with HOD. It may be necessary to evaluate repeated radiographs to establish a diagnosis of HOD. Most HOD-affected Weimaraners had resolution of the condition with physeal closure.
authors.affiliation: Department of Population Health and Reproduction, University of California-Davis, Davis CA 95616, USA. nsafra@ucdavis.edu
authors.forename: Noa
authors.initials: N
authors.lastname: Safra
authors.forename: Eric G
authors.initials: EG
authors.lastname: Johnson
authors.forename: Lisa
authors.initials: L
authors.lastname: Lit
authors.forename: Oded
authors.initials: O
authors.lastname: Foreman
authors.forename: Zena T
authors.initials: ZT
authors.lastname: Wolf
authors.forename: Miriam
authors.initials: M
authors.lastname: Aguilar
authors.forename: Nili
authors.initials: N
authors.lastname: Karmi
authors.forename: Carrie J
authors.initials: CJ
authors.lastname: Finno
authors.forename: Danika L
authors.initials: DL
authors.lastname: Bannasch
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy / Q000473:pathology*; D004285:Dogs; D005260:Female; D008297:Male
chemical_list: D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal